Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Commun Biol. 2021 Feb 12;4(1):197. doi: 10.1038/s42003-021-01736-8.

Abstract

In light of the recent accumulated knowledge on SARS-CoV-2 and its mode of human cells invasion, the binding of viral spike glycoprotein to human Angiotensin Converting Enzyme 2 (hACE2) receptor plays a central role in cell entry. We designed a series of peptides mimicking the N-terminal helix of hACE2 protein which contains most of the contacting residues at the binding site, exhibiting a high helical folding propensity in aqueous solution. Our best peptide-mimics are able to block SARS-CoV-2 human pulmonary cell infection with an inhibitory concentration (IC50) in the nanomolar range upon binding to the virus spike protein with high affinity. These first-in-class blocking peptide mimics represent powerful tools that might be used in prophylactic and therapeutic approaches to fight the coronavirus disease 2019 (COVID-19).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Angiotensin-Converting Enzyme 2 / chemistry*
  • COVID-19 / virology*
  • Cell Line
  • Circular Dichroism
  • Humans
  • Peptides / chemical synthesis
  • Peptides / chemistry
  • Peptides / metabolism
  • Peptides / pharmacology*
  • Protein Binding / drug effects
  • Protein Structure, Secondary
  • SARS-CoV-2 / physiology*
  • Spike Glycoprotein, Coronavirus / metabolism
  • Virus Replication / drug effects

Substances

  • Peptides
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2